Bristol-Myers Squibb (NYSE: BMY) held its Q2 2026 earnings call on July 30, 2026, with two headline pipeline changes: the Factor XIa inhibitor milvexian atrial fibrillation readout slipped to Q1 2027, and the Cobenfy Alzheimer's psychosis program was pushed broadly into 2027, leaving admilparant's idiopathic pulmonary fibrosis (IPF) data as the most consequential near-term catalyst.

Total revenue for Q2 2026 rose 5% year-on-year to approximately USD 13 billion, with growth portfolio sales up 14% to USD 7.6 billion. BMS raised full-year revenue and adjusted earnings per share guidance, citing strong demand across the growth portfolio and higher projected apixaban (Eliquis) growth of 20% to 25%.

Key Strategic Signals

  • Milvexian AFib readout moved to Q1 2027: The event-driven atrial fibrillation study now requires 430 primary stroke/embolism events and 530 bleeding events before database lock, and both endpoints are accruing more slowly than initially projected. Chief Medical Officer Cristian Massacesi said the slower event rate is a favorable signal, drawing an analogy to a competing Factor XIa program in atrial fibrillation that was stopped by its data monitoring committee (DMC) after events trended adversely. Massacesi said the independent DMC "continues to endorse the conduction of the study" and that the program remains designed and powered to show a hazard ratio of 1 on strokes, with superiority on bleeding expected. Chief Commercialization Officer Adam Lenkowsky said BMS already has the commercial infrastructure for the atrial fibrillation market in place via Eliquis, and that the Eliquis loss of exclusivity in April 2028 aligns with the milvexian filing and launch timeline.
  • Admilparant is now the highest-stakes near-term readout: Phase III IPF data are expected in H2 2026, with progressive pulmonary fibrosis (PPF) data to follow within months in early 2027. The study tests two doses — 60 mg (the Phase II-derived dose) and 120 mg, which was introduced at Phase III initiation based on modeling suggesting dose-response activity. Massacesi said the DMC cleared the 120 mg dose on safety and that blinded safety event rates are reassuring, giving what he described as "two shots on goal." Lenkowsky framed the competitive context around nerandomilast (Jascayd), noting that over 50% of new Jascayd starts are coming after generic nintedanib or pirfenidone as switch or add-on treatments, suggesting a growing second-line market that admilparant could enter as a first branded option with combination potential. Management said the LPA1 mechanism targets fibrotic, inflammatory, and epithelial repair pathways, which they characterized as distinct from current agents.
  • Cobenfy's (xanomeline and trospium chloride) Alzheimer's psychosis program delayed across 2027: ADEPT-2 and ADEPT-4 enrollment was slowed by quality-control measures applied to patient selection and trial conduct; ADEPT-1 is event-driven and events are accruing more slowly than projected. Massacesi said quality preservation is a deliberate strategy to maximize the probability of registration success. An interim analysis for ADEPT-1 remains possible late this year, and open-label safety and efficacy data from ADEPT-1's lead-in period and the ADEPT-3 rollover study will be presented at a medical meeting later in 2026. Phase III BALSAM-1 and BALSAM-2 studies of Cobenfy in bipolar I disorder are enrolling well and are expected to read out in H1 2027.
  • CELMoD platform approaching dual commercial launch: Iberdomide carries an August 17 PDUFA date, and mezigdomide received FDA NDA acceptance with a May 13, 2027 PDUFA date following the Phase III SUCCESSOR-2 data showing more than 50% reduction in risk of disease progression or death versus standard of care. Lenkowsky said the commercial goal is to make iberdomide and mezigdomide foundational in multiple myeloma, replacing lenalidomide (Revlimid) and pomalidomide (Pomalyst) in leading triplet regimens in combination with daratumumab. He added that progression-free survival data for iberdomide are expected within months of a potential approval, which may accelerate community uptake. A third CELMoD, golcadomide, is in development for first-line large B-cell lymphoma and second-line follicular lymphoma.

Analyst Pressure Points

  • Milvexian hazard ratio threshold: JPMorgan's Christopher Schott asked management to frame what level of efficacy data would constitute a broad commercial opportunity versus a narrower underserved-patient play. Lenkowsky declined to anchor on a specific hazard ratio, saying physicians and payers are focused on clinically meaningful reductions in major bleeding events and hospitalizations rather than a numerical threshold. He said the study was designed to demonstrate superior bleeding versus Eliquis with comparable efficacy, and that a favorable profile would allow physicians to initiate and maintain anticoagulation more confidently, including in high-risk subgroups such as elderly patients, those with low body weight, and those with renal impairment.
  • Study conduct and timeline delays: TD Cowen's Steve Scala asked whether the milvexian and Cobenfy delays were related to lingering study conduct issues following prior Phase III setbacks. Massacesi said the two programs are unrelated to each other and to prior execution problems: milvexian is purely event-driven, and Cobenfy's ADEPT-2 and ADEPT-4 delays reflect a deliberate quality-first enrollment approach. CEO Christopher Boerner endorsed Massacesi's first year, citing progress on scientific talent, operational discipline, and R&D infrastructure.

Forward-Looking Catalysts

  • Admilparant Phase III IPF data (H2 2026): The first pivotal readout for the LPA1 antagonist will determine whether BMS can enter a market management estimates at roughly USD 4 billion today and potentially USD 8 to 10 billion by the mid-2030s. The dual-dose design and a blinded safety profile described as comparable to placebo in Phase II support management's confidence, but the readout carries binary risk for what management described as a potentially foundational asset.
  • Iberdomide PDUFA date (August 17, 2026): Approval would deliver the first commercialized cereblon E3 ligase modulator (CELMoD) in multiple myeloma. Management said commercial teams are launch-ready and that the drug's oral convenience and tolerability profile suit community oncology settings where 70% to 80% of myeloma patients are treated.
  • Pumitamig program expansion: BMS is initiating a fourth global Phase III study in first-line EGFR-mutant non-small cell lung cancer (NSCLC) and a new Phase II novel-novel study combining pumitamig with the CCR8 antibody imzokitug. Phase II data from pumitamig in combination with chemotherapy for first-line NSCLC were presented at ASCO in June, and CFO David Elkins noted that accelerated prelaunch spending on CELMoDs and the expanding pumitamig program contributed to a slight increase in projected full-year operating expenses.

Access the AllSci platform to explore the science behind the news.

Spot something wrong? Report an issue with this article